FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306668017> ?p ?o ?g. }

• W4306668017 endingPage "107602962211325" @default.
• W4306668017 startingPage "107602962211325" @default.
• W4306668017 abstract "Non-vitamin K antagonist oral anticoagulants (NOACs) were developed as an alternative to warfarin to prevent thromboembolism in patients with atrial fibrillation (AF), prosthetic heart valves, venous thromboembolism (VTE), or other thrombotic disorders. The aim of this study is to explore the trends in prescribing OACs, including warfarin and NOACs, in Shanghai, China.Prescription data of OACs were retrospectively collected from Rx Analysis System from 2010 to 2020 in Shanghai, China. Comparisons were made on the trends of each OACs according to different indications, age groups, and hospital grades. The costs and the contribution of individual OACs were also explored.Growing trends in overall prescriptions for OACs were observed. The prescriptions of NOACs were significantly increased since 2016, while the prescriptions of warfarin kept decreasing since 2017. A highly statistically significant increase in prescriptions of Rivaroxaban was observed from 2016 to 2020 (P < .001). Despite the price reduction of rivaroxaban in 2018, the total cost of rivaroxaban continued to rise (P < .001). Rivaroxaban emerged as a preferred NOAC in both indications of AF and VTE, and accounted for more than three-quarters of the total costs for OACs since 2019. Compared with rivaroxaban, the prescription numbers of dabigatran and apixaban were much smaller, and the growth of prescriptions were much slower. Differences in prescribing patterns in different indications, age groups, and grades of hospitals were also founded.There has been a rapid increase in the use of OAC over the last 11 years in Shanghai, China. NOACs have been adopted rapidly, and have been gradually replacing warfarin. Warfarin remains the top choice for certain patients with valvular heart disease. Future studies are warranted considering changes in the OAC use in a larger scale, as well as the rationality and its influence factors on OAC use." @default.
• W4306668017 created "2022-10-19" @default.
• W4306668017 creator A5009043001 @default.
• W4306668017 creator A5022198742 @default.
• W4306668017 creator A5048328066 @default.
• W4306668017 creator A5049136138 @default.
• W4306668017 creator A5054352845 @default.
• W4306668017 creator A5055781139 @default.
• W4306668017 creator A5057548382 @default.
• W4306668017 date "2022-01-01" @default.
• W4306668017 modified "2023-10-18" @default.
• W4306668017 title "Prescribing Trends of Oral Anticoagulants from 2010 to 2020 in Shanghai, China: A Retrospective Study" @default.
• W4306668017 cites W2040690190 @default.
• W4306668017 cites W2109524995 @default.
• W4306668017 cites W2469014440 @default.
• W4306668017 cites W2519749746 @default.
• W4306668017 cites W2582505536 @default.
• W4306668017 cites W2622826012 @default.
• W4306668017 cites W2734695153 @default.
• W4306668017 cites W2735261543 @default.
• W4306668017 cites W2736956220 @default.
• W4306668017 cites W2737130990 @default.
• W4306668017 cites W2739421744 @default.
• W4306668017 cites W2750718596 @default.
• W4306668017 cites W2769275060 @default.
• W4306668017 cites W2773266137 @default.
• W4306668017 cites W2778779964 @default.
• W4306668017 cites W2790204922 @default.
• W4306668017 cites W2802753422 @default.
• W4306668017 cites W2883062654 @default.
• W4306668017 cites W2921813015 @default.
• W4306668017 cites W2951901519 @default.
• W4306668017 cites W2954818983 @default.
• W4306668017 cites W2956053593 @default.
• W4306668017 cites W2981617427 @default.
• W4306668017 cites W2999809843 @default.
• W4306668017 cites W3021583806 @default.
• W4306668017 cites W3034331236 @default.
• W4306668017 cites W3049524407 @default.
• W4306668017 cites W3082188176 @default.
• W4306668017 cites W3098781229 @default.
• W4306668017 cites W3099518860 @default.
• W4306668017 cites W3123126572 @default.
• W4306668017 cites W3134910881 @default.
• W4306668017 cites W3135243964 @default.
• W4306668017 cites W3159673032 @default.
• W4306668017 cites W3174015221 @default.
• W4306668017 cites W3188073003 @default.
• W4306668017 cites W3193235957 @default.
• W4306668017 cites W3205622641 @default.
• W4306668017 cites W3212745944 @default.
• W4306668017 cites W3213445886 @default.
• W4306668017 cites W4200102179 @default.
• W4306668017 cites W4210242902 @default.
• W4306668017 cites W826970266 @default.
• W4306668017 doi "https://doi.org/10.1177/10760296221132551" @default.
• W4306668017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36250531" @default.
• W4306668017 hasPublicationYear "2022" @default.
• W4306668017 type Work @default.
• W4306668017 citedByCount "4" @default.
• W4306668017 countsByYear W43066680172022 @default.
• W4306668017 countsByYear W43066680172023 @default.
• W4306668017 crossrefType "journal-article" @default.
• W4306668017 hasAuthorship W4306668017A5009043001 @default.
• W4306668017 hasAuthorship W4306668017A5022198742 @default.
• W4306668017 hasAuthorship W4306668017A5048328066 @default.
• W4306668017 hasAuthorship W4306668017A5049136138 @default.
• W4306668017 hasAuthorship W4306668017A5054352845 @default.
• W4306668017 hasAuthorship W4306668017A5055781139 @default.
• W4306668017 hasAuthorship W4306668017A5057548382 @default.
• W4306668017 hasBestOaLocation W43066680171 @default.
• W4306668017 hasConcept C126322002 @default.
• W4306668017 hasConcept C167135981 @default.
• W4306668017 hasConcept C194828623 @default.
• W4306668017 hasConcept C2426938 @default.
• W4306668017 hasConcept C2776301958 @default.
• W4306668017 hasConcept C2776704044 @default.
• W4306668017 hasConcept C2778661090 @default.
• W4306668017 hasConcept C2778810321 @default.
• W4306668017 hasConcept C2779161974 @default.
• W4306668017 hasConcept C2780638905 @default.
• W4306668017 hasConcept C2780868729 @default.
• W4306668017 hasConcept C2991741193 @default.
• W4306668017 hasConcept C71924100 @default.
• W4306668017 hasConcept C98274493 @default.
• W4306668017 hasConceptScore W4306668017C126322002 @default.
• W4306668017 hasConceptScore W4306668017C167135981 @default.
• W4306668017 hasConceptScore W4306668017C194828623 @default.
• W4306668017 hasConceptScore W4306668017C2426938 @default.
• W4306668017 hasConceptScore W4306668017C2776301958 @default.
• W4306668017 hasConceptScore W4306668017C2776704044 @default.
• W4306668017 hasConceptScore W4306668017C2778661090 @default.
• W4306668017 hasConceptScore W4306668017C2778810321 @default.
• W4306668017 hasConceptScore W4306668017C2779161974 @default.
• W4306668017 hasConceptScore W4306668017C2780638905 @default.
• W4306668017 hasConceptScore W4306668017C2780868729 @default.
• W4306668017 hasConceptScore W4306668017C2991741193 @default.
• W4306668017 hasConceptScore W4306668017C71924100 @default.

• next